UCLA Researcher Peter Tontonoz to Receive American Heart Association's 2025 Basic Research Prize
TL;DR
Dr. Tontonoz's discoveries of novel cholesterol mechanisms like Aster protein offer pharmaceutical companies competitive advantages in developing next-generation therapies beyond statins.
Dr. Tontonoz's research systematically identified key proteins like PPAR-gamma and SREBP1c that regulate lipid metabolism through precise cellular mechanisms and pathways.
This research advances global heart health by enabling more precise treatments for cardiovascular diseases, improving outcomes for millions of patients worldwide.
Dr. Tontonoz discovered Aster, a novel cholesterol transfer protein that moves dietary lipids from membranes to cellular processing centers.
Found this article helpful?
Share it with your network and spread the knowledge!
Peter Tontonoz, M.D., Ph.D., distinguished professor at the University of California, Los Angeles David Geffen School of Medicine and UCLA Health, will receive the Basic Research Prize from the American Heart Association during its Scientific Sessions 2025 in New Orleans. The award recognizes Dr. Tontonoz's groundbreaking contributions to understanding cholesterol, fatty acid, and phospholipid metabolism, which have transformed scientific understanding of cardiometabolic diseases.
Dr. Tontonoz's research has uncovered fundamental mechanisms of how the body maintains fat balance from cellular to systemic levels, leading to improved treatments for heart disease, diabetes, and related conditions. His identification of an E3 ligase that targets and degrades the LDL receptor has opened new avenues for cholesterol-lowering therapies beyond statins. Additionally, his work on the nuclear receptor Liver X Receptor demonstrated the critical intersection between immunology and metabolism, helping establish the field of immunometabolism.
Among his most significant recent discoveries is the characterization of a novel cholesterol transfer protein called Aster, which moves cholesterol from the plasma membrane to the endoplasmic reticulum and serves as a key factor in dietary lipid uptake. Dr. Tontonoz also discovered important membrane phospholipid remodeling enzymes that affect intestinal and liver physiology. These collective insights have deepened understanding of cardiovascular and metabolic diseases, paving the way for more precise and effective treatments that could benefit millions of patients worldwide.
Stacey E. Rosen, M.D., FAHA, the American Heart Association's 2025-2026 volunteer president, stated that Dr. Tontonoz's scientific contributions to lipid metabolism impact every individual and that he is widely regarded as a brilliant and innovative leader in cardiovascular research. Dr. Tontonoz expressed that lipids such as cholesterol are critical determinants of cardiovascular disease, and his work aims to illuminate how fat-related processes influence both normal tissue function and disease pathology to find new prevention and treatment approaches.
Beyond his laboratory achievements, Dr. Tontonoz has mentored numerous scientists who now lead research groups throughout the scientific community. He serves on several National Institutes of Health study sections and editorial boards for peer-reviewed journals including the Journal of Clinical Investigation, the Proceedings of the National Academy of Sciences, and Genes & Development. The American Heart Association Scientific Sessions 2025, where Dr. Tontonoz will receive his award, represents a premier global exchange of the latest scientific advancements in cardiovascular science and will be held November 7-10 in New Orleans.
Curated from NewMediaWire
